Molecular mechanisms in the pathogenesis of alzheimer’s disease and Tauopathies-Prion-Like seeded aggregation and phosphorylation

Biomolecules

Volumn 6, Issue 2, 2016, Pages

  Hasegawa, Masato ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Amyloid 3; APP 5; Fibril 4; MAPT; Prion 2; Synuclein; TDP 43

Indexed keywords

ALKALINE PHOSPHATASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PRION PROTEIN; TAU PROTEIN; AMYLOID; PRION;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CORTICOBASAL DEGENERATION; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; PARKINSONISM; PICK PRESENILE DEMENTIA; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; TAUOPATHY; BRAIN; CHEMISTRY; DEMENTIA; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PRION;

AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; BRAIN; DEMENTIA; HUMANS; MUTATION; PHOSPHORYLATION; PRIONS; TAU PROTEINS; TAUOPATHIES;

EID: 85012066425     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom6020024     Document Type: Review

References (95)

1. Braak, H, Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82, 239-259. [CrossRef] [PubMed]
2. Goate, A, Chartier-Harlin, M.C, Mullan, M, Brown, J, Crawford, F, Fidani, L, Giuffra, L, Haynes, A, Irving, N, James, L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991, 349, 704-706. [CrossRef] [PubMed]
3. Hardy, J, Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci. 1991, 12, 383-388. [CrossRef]
4. Hardy, J.A, Higgins, G.A. Alzheimer’s disease: The amyloid cascade hypothesis. Science 1992, 256, 184-185. [CrossRef] [PubMed]
5. Hardy, J, Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science 2002, 297, 353-356. [CrossRef] [PubMed]
6. Sherrington, R, Rogaev, E.I, Liang, Y, Rogaeva, E.A, Levesque, G, Ikeda, M, Chi, H, Lin, C, Li, G, Holman, K, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995, 375, 754-760. [CrossRef] [PubMed]
7. Levy-Lahad, E, Wasco, W, Poorkaj, P, Romano, D.M, Oshima, J, Pettingell, W.H, Yu, C.E, Jondro, P.D, Schmidt, S.D, Wang, K, et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 1995, 269, 973-977. [CrossRef] [PubMed]
8. Rogaev, E.I, Sherrington, R, Rogaeva, E.A, Levesque, G, Ikeda, M, Liang, Y, Chi, H, Lin, C, Holman, K, Tsuda, T, et al. Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 1995, 376, 775-778. [CrossRef] [PubMed]
9. De Strooper, B, Saftig, P, Craessaerts, K, Vanderstichele, H, Guhde, G, Annaert, W, von Figura, K, van Leuven, F. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998, 391, 387-390. [CrossRef] [PubMed]
10. De Strooper, B, Annaert, W, Cupers, P, Saftig, P, Craessaerts, K, Mumm, J.S, Schroeter, E.H, Schrijvers, V, Wolfe, M.S, Ray, W.J, et al. A presenilin-1-dependent-secretase-like protease mediates release of notch intracellular domain. Nature 1999, 398, 518-522. [CrossRef] [PubMed]
11. Wolfe, M.S, Xia, W, Ostaszewski, B.L, Diehl, T.S, Kimberly, W.T, Selkoe, D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and β-secretase activity. Nature 1999, 398, 513-517. [CrossRef] [PubMed]
12. Chetelat, G. Alzheimer disease: Aβ-independent processes-rethinking preclinical AD. Nat. Rev. Neurol. 2013, 9, 123-124. [CrossRef] [PubMed]
13. Giacobini, E, Gold, G. Alzheimer disease therapy—moving from amyloid-β to tau. Nat. Rev. Neurol. 2013, 9, 677-686. [CrossRef] [PubMed]
14. Herrup, K. The case for rejecting the amyloid cascade hypothesis. Nat. Neurosci. 2015, 18, 794-799. [CrossRef] [PubMed]
15. Holmes, C, Boche, D, Wilkinson, D, Yadegarfar, G, Hopkins, V, Bayer, A, Jones, R.W, Bullock, R, Love, S, Neal, J.W, et al. Long-term effects of Aβ42 immunisation in Alzheimer’s disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372, 216-223. [CrossRef]
16. Ostrowitzki, S, Deptula, D, Thurfjell, L, Barkhof, F, Bohrmann, B, Brooks, D.J, Klunk, W.E, Ashford, E, Yoo, K, Xu, Z.X, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 2012, 69, 198-207. [CrossRef] [PubMed]
17. Doody, R.S, Raman, R, Farlow, M, Iwatsubo, T, Vellas, B, Joffe, S, Kieburtz, K, He, F, Sun, X, Thomas, R.G, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N. Engl. J. Med. 2013, 369, 341-350. [CrossRef] [PubMed]
18. Salloway, S, Sperling, R, Gilman, S, Fox, N.C, Blennow, K, Raskind, M, Sabbagh, M, Honig, L.S, Doody, R, van Dyck, C.H, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73, 2061-2070. [CrossRef] [PubMed]
19. Doody, R.S, Thomas, R.G, Farlow, M, Iwatsubo, T, Vellas, B, Joffe, S, Kieburtz, K, Raman, R, Sun, X, Aisen, P.S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 2014, 370, 311-321. [CrossRef] [PubMed]
20. Goedert, M. Neurodegeneration. Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and β-synuclein. Science 2015. [CrossRef] [PubMed]
21. Holmes, B.B, Diamond, M.I. Prion-like properties of tau protein: The importance of extracellular tau as a therapeutic target. J. Biol. Chem. 2014, 289, 19855-19861. [CrossRef] [PubMed]
22. Jucker, M, Walker, L.C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013, 501, 45-51. [CrossRef] [PubMed]
23. Prusiner, S.B. Biology and genetics of prions causing neurodegeneration. Annu. Rev. Genet. 2013, 47, 601-623. [CrossRef] [PubMed]
24. Frost, B, Diamond, M.I. Prion-like mechanisms in neurodegenerative diseases. Nat. Rev. Neurosci. 2010, 11, 155-159. [CrossRef] [PubMed]
25. Goedert, M, Spillantini, M.G, Jakes, R, Rutherford, D, Crowther, R.A. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron 1989, 3, 519-526. [CrossRef]
26. Weingarten, M.D, Lockwood, A.H, Hwo, S.Y, Kirschner, M.W. A protein factor essential for microtubule assembly. Proc. Nat. Acad. Sci. USA 1975, 72, 1858-1862. [CrossRef] [PubMed]
27. Goedert, M, Jakes, R. Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 1990, 9, 4225-4230. [PubMed]
28. Iqbal, K, Liu, F, Gong, C.X. Tau and neurodegenerative disease: The story so far. Nat. Rev. Neurol. 2016, 12, 15-27. [CrossRef] [PubMed]
29. Goedert, M. Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci. 1993, 16, 460-465. [CrossRef]
30. Goedert, M, Spillantini, M.G, Hasegawa, M, Jakes, R, Crowther, R.A, Klug, A. Molecular dissection of the neurofibrillary lesions of Alzheimer’s disease. Cold Spring Harb. Symp. Quant. Biol. 1996, 61, 565-573. [PubMed]
31. Crowther, R.A, Wischik, C.M. Image reconstruction of the Alzheimer paired helical filament. EMBO J. 1985, 4, 3661-3665. [PubMed]
32. Wischik, C.M, Crowther, R.A. Subunit structure of the Alzheimer tangle. Br. Med. Bull. 1986, 42, 51-56. [PubMed]
33. Wischik, C.M, Novak, M, Edwards, P.C, Klug, A, Tichelaar, W, Crowther, R.A. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc. Nat. Acad. Sci. USA 1988, 85, 4884-4888. [CrossRef] [PubMed]
34. Wischik, C.M, Novak, M, Thogersen, H.C, Edwards, P.C, Runswick, M.J, Jakes, R, Walker, J.E, Milstein, C, Roth, M, Klug, A. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc. Nat. Acad. Sci. USA 1988, 85, 4506-4510. [CrossRef] [PubMed]
35. Crowther, T, Goedert, M, Wischik, C.M. The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer’s disease. Ann. Med. 1989, 21, 127-132. [CrossRef] [PubMed]
36. Goedert, M, Spillantini, M.G, Potier, M.C, Ulrich, J, Crowther, R.A. Cloning and sequencing of the cdna encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau protein mrnas in human brain. EMBO J. 1989, 8, 393-399. [PubMed]
37. Greenberg, S.G, Davies, P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Nat. Acad. Sci. USA 1990, 87, 5827-5831. [CrossRef] [PubMed]
38. Lee, V.M, Balin, B.J, Otvos, L., Jr, Trojanowski, J.Q. A68: A major subunit of paired helical filaments and derivatized forms of normal tau. Science 1991, 251, 675-678. [CrossRef] [PubMed]
39. Hasegawa, M, Morishima-Kawashima, M, Takio, K, Suzuki, M, Titani, K, Ihara, Y. Protein sequence and mass spectrometric analyses of tau in the Alzheimer’s disease brain. J. Biol. Chem. 1992, 267, 17047-17054. [PubMed]
40. Hasegawa, M, Watanabe, A, Takio, K, Suzuki, M, Arai, T, Titani, K, Ihara, Y. Characterization of two distinct monoclonal antibodies to paired helical filaments: Further evidence for fetal-type phosphorylation of the tau in paired helical filaments. J. Neurochem. 1993, 60, 2068-2077. [CrossRef] [PubMed]
41. Morishima-Kawashima, M, Hasegawa, M, Takio, K, Suzuki, M, Titani, K, Ihara, Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 1993, 10, 1151-1160. [CrossRef]
42. Morishima-Kawashima, M, Hasegawa, M, Takio, K, Suzuki, M, Yoshida, H, Titani, K, Ihara, Y. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 1995, 270, 823-829. [CrossRef] [PubMed]
43. Dan, A, Takahashi, M, Masuda-Suzukake, M, Kametani, F, Nonaka, T, Kondo, H, Akiyama, H, Arai, T, Mann, D.M, Saito, Y, et al. Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimer’s disease brain. Acta Neuropathol. Commun. 2013. [CrossRef] [PubMed]
44. Goedert, M, Spillantini, M.G, Cairns, N.J, Crowther, R.A. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron 1992, 8, 159-168. [CrossRef]
45. Biernat, J, Mandelkow, E.M, Schroter, C, Lichtenberg-Kraag, B, Steiner, B, Berling, B, Meyer, H, Mercken, M, Vandermeeren, A, Goedert, M, et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 1992, 11, 1593-1597. [PubMed]
46. Bramblett, G.T, Goedert, M, Jakes, R, Merrick, S.E, Trojanowski, J.Q, Lee, V.M. Abnormal tau phosphorylation at Ser396 in Alzheimer’s disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993, 10, 1089-1099. [CrossRef]
47. Goedert, M, Jakes, R, Crowther, R.A, Six, J, Lubke, U, Vandermeeren, M, Cras, P, Trojanowski, J.Q, Lee, V.M. The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc. Nat. Acad. Sci. USA 1993, 90, 5066-5070. [CrossRef] [PubMed]
48. Morishima-Kawashima, M, Hasegawa, M, Takio, K, Suzuki, M, Yoshida, H, Watanabe, A, Titani, K, Ihara, Y. Hyperphosphorylation of tau in PHF. Neurobiol. Aging 1995, 16, 365-371. [CrossRef]
49. Iwatsubo, T, Hasegawa, M, Ihara, Y. Neuronal and glial tau-positive inclusions in diverse neurologic diseases share common phosphorylation characteristics. Acta Neuropathol. 1994, 88, 129-136. [CrossRef] [PubMed]
50. Buee, L, Delacourte, A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick’s disease. Brain Pathol. 1999, 9, 681-693. [CrossRef] [PubMed]
51. Lee, V.M, Goedert, M, Trojanowski, J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24, 1121-1159. [CrossRef] [PubMed]
52. Goedert, M, Hasegawa, M. The tauopathies: Toward an experimental animal model. Am. J. Pathol. 1999, 154, 1-6. [CrossRef]
53. Kovacs, G.G. Invited review: Neuropathology of tauopathies: Principles and practice. Neuropathol. Appl. Neurobiol. 2015, 41, 3-23. [CrossRef] [PubMed]
54. Umeda, Y, Taniguchi, S, Arima, K, Piao, Y.S, Takahashi, H, Iwatsubo, T, Mann, D, Hasegawa, M. Alterations in human tau transcripts correlate with those of neurofilament in sporadic tauopathies. Neurosci. Lett. 2004, 359, 151-154. [CrossRef] [PubMed]
55. Poorkaj, P, Bird, T.D, Wijsman, E, Nemens, E, Garruto, R.M, Anderson, L, Andreadis, A, Wiederholt, W.C, Raskind, M, Schellenberg, G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 1998, 43, 815-825. [CrossRef] [PubMed]
56. Spillantini, M.G, Goedert, M, Crowther, R.A, Murrell, J.R, Farlow, M.R, Ghetti, B. Familial multiple system tauopathy with presenile dementia: A disease with abundant neuronal and glial tau filaments. Proc. Nat. Acad. Sci. USA 1997, 94, 4113-4118. [CrossRef] [PubMed]
57. Hutton, M, Lendon, C.L, Rizzu, P, Baker, M, Froelich, S, Houlden, H, Pickering-Brown, S, Chakraverty, S, Isaacs, A, Grover, A, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393, 702-705. [CrossRef] [PubMed]
58. Spillantini, M.G, Murrell, J.R, Goedert, M, Farlow, M.R, Klug, A, Ghetti, B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Nat. Acad. Sci. USA 1998, 95, 7737-7741. [CrossRef] [PubMed]
59. Goedert, M, Crowther, R.A, Spillantini, M.G. Tau mutations cause frontotemporal dementias. Neuron 1998, 21, 955-958. [CrossRef]
60. Goedert, M, Ghetti, B, Spillantini, M.G. Frontotemporal dementia: Implications for understanding Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012. [CrossRef] [PubMed]
61. Taniguchi-Watanabe, S, Arai, T, Kametani, F, Nonaka, T, Masuda-Suzukake, M, Tarutani, A, Murayama, S, Saito, Y, Arima, K, Yoshida, M, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016, 131, 267-280. [CrossRef] [PubMed]
62. Watanabe, A, Hasegawa, M, Suzuki, M, Takio, K, Morishima-Kawashima, M, Titani, K, Arai, T, Kosik, K.S, Ihara, Y. In vivo phosphorylation sites in fetal and adult rat tau. J. Biol. Chem. 1993, 268, 25712-25717. [PubMed]
63. Matsuo, E.S, Shin, R.W, Billingsley, M.L, van deVoorde, A, O’Connor, M, Trojanowski, J.Q, Lee, V.M. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau. Neuron 1994, 13, 989-1002. [CrossRef]
64. Yamamoto, H, Hasegawa, M, Ono, T, Tashima, K, Ihara, Y, Miyamoto, E. Dephosphorylation of fetal-tau and paired helical filaments-tau by protein phosphatases 1 and 2A and calcineurin. J. Biochem. 1995, 118, 1224-1231. [PubMed]
65. Von Bergen, M, Friedhoff, P, Biernat, J, Heberle, J, Mandelkow, E.M, Mandelkow, E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif 306VQIVYK311 forming β structure. Proc. Nat. Acad. Sci. USA 2000, 97, 5129-5134. [CrossRef] [PubMed]
66. Arai, T, Ikeda, K, Akiyama, H, Nonaka, T, Hasegawa, M, Ishiguro, K, Iritani, S, Tsuchiya, K, Iseki, E, Yagishita, S, et al. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann. Neurol. 2004, 55, 72-79. [CrossRef] [PubMed]
67. Ksiezak-Reding, H, Yen, S.H. Structural stability of paired helical filaments requires microtubule-binding domains of tau: A model for self-association. Neuron 1991, 6, 717-728. [CrossRef]
68. Hasegawa, M, Watanabe, S, Kondo, H, Akiyama, H, Mann, D.M, Saito, Y, Murayama, S. 3r and 4r tau isoforms in paired helical filaments in Alzheimer’s disease. Acta Neuropathol. 2014, 127, 303-305. [CrossRef] [PubMed]
69. Probst, A, Tolnay, M, Langui, D, Goedert, M, Spillantini, M.G. Pick’s disease: Hyperphosphorylated tau protein segregates to the somatoaxonal compartment. Acta Neuropathol. 1996, 92, 588-596. [CrossRef] [PubMed]
70. Arai, T, Ikeda, K, Akiyama, H, Tsuchiya, K, Iritani, S, Ishiguro, K, Yagishita, S, Oda, T, Odawara, T, Iseki, E. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer’s disease, Pick’s disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. 2003, 105, 489-498. [PubMed]
71. Aoyagi, H, Hasegawa, M, Tamaoka, A. Fibrillogenic nuclei composed of P301L mutant tau induce elongation of P301L tau but not wild-type tau. J. Biol. Chem. 2007, 282, 20309-20318. [CrossRef] [PubMed]
72. Frost, B, Jacks, R.L, Diamond, M.I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 2009, 284, 12845-12852. [CrossRef] [PubMed]
73. Nonaka, T, Watanabe, S.T, Iwatsubo, T, Hasegawa, M. Seeded aggregation and toxicity of β-synuclein and tau: Cellular models of neurodegenerative diseases. J. Biol. Chem. 2010, 285, 34885-34898. [CrossRef] [PubMed]
74. Clavaguera, F, Bolmont, T, Crowther, R.A, Abramowski, D, Frank, S, Probst, A, Fraser, G, Stalder, A.K, Beibel, M, Staufenbiel, M, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 2009, 11, 909-913. [CrossRef] [PubMed]
75. Clavaguera, F, Akatsu, H, Fraser, G, Crowther, R.A, Frank, S, Hench, J, Probst, A, Winkler, D.T, Reichwald, J, Staufenbiel, M, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Nat. Acad. Sci. USA 2013, 110, 9535-9540. [CrossRef] [PubMed]
76. Sanders, D.W, Kaufman, S.K, DeVos, S.L, Sharma, A.M, Mirbaha, H, Li, A, Barker, S.J, Foley, A.C, Thorpe, J.R, Serpell, L.C, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 2014, 82, 1271-1288. [CrossRef] [PubMed]
77. Goedert, M, Clavaguera, F, Tolnay, M. The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci. 2010, 33, 317-325. [CrossRef] [PubMed]
78. Aguzzi, A, Rajendran, L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009, 64, 783-790. [CrossRef] [PubMed]
79. Brundin, P, Melki, R, Kopito, R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat. Rev. Mol. Cell Biol. 2010, 11, 301-307. [CrossRef] [PubMed]
80. Takahashi, M, Miyata, H, Kametani, F, Nonaka, T, Akiyama, H, Hisanaga, S, Hasegawa, M. Extracellular association of app and tau fibrils induces intracellular aggregate formation of tau. Acta Neuropathol. 2015, 129, 895-907. [CrossRef] [PubMed]
81. Braak, H, Del Tredici, K. The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol. 2011, 121, 171-181. [CrossRef] [PubMed]
82. Mann, D.M, Hardy, J. Amyloid or tau: The chicken or the egg? Acta Neuropathol. 2013, 126, 609-613. [CrossRef] [PubMed]
83. Braak, H, Del Tredici, K. Reply: The early pathological process in sporadic Alzheimer’s disease. Acta Neuropathol. 2013, 126, 615-618. [CrossRef] [PubMed]
84. Braak, H, Zetterberg, H, Del Tredici, K, Blennow, K. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol. 2013, 126, 631-641. [CrossRef] [PubMed]
85. Jellinger, K.A, Alafuzoff, I, Attems, J, Beach, T.G, Cairns, N.J, Crary, J.F, Dickson, D.W, Hof, P.R, Hyman, B.T, Jack, C.R., Jr, et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol. 2015, 129, 757-762. [CrossRef] [PubMed]
86. Duyckaerts, C, Braak, H, Brion, J.P, Buee, L, Del Tredici, K, Goedert, M, Halliday, G, Neumann, M, Spillantini, M.G, Tolnay, M, et al. PART is part of Alzheimer disease. Acta Neuropathol. 2015, 129, 749-756. [CrossRef] [PubMed]
87. Braak, H, Del Tredici, K. Amyloid-β may be released from non-junctional varicosities of axons generated from abnormal tau-containing brainstem nuclei in sporadic Alzheimer’s disease: A hypothesis. Acta Neuropathol. 2013, 126, 303-306. [CrossRef] [PubMed]
88. Taniguchi, S, Suzuki, N, Masuda, M, Hisanaga, S, Iwatsubo, T, Goedert, M, Hasegawa, M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 2005, 280, 7614-7623. [CrossRef] [PubMed]
89. Masuda, M, Suzuki, N, Taniguchi, S, Oikawa, T, Nonaka, T, Iwatsubo, T, Hisanaga, S, Goedert, M, Hasegawa, M. Small molecule inhibitors of β-synuclein filament assembly. Biochemistry 2006, 45, 6085-6094. [CrossRef] [PubMed]
90. Harrington, C.R, Storey, J.M, Clunas, S, Harrington, K.A, Horsley, D, Ishaq, A, Kemp, S.J, Larch, C.P, Marshall, C, Nicoll, S.L, et al. Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer disease. J. Biol. Chem. 2015, 290, 10862-10875. [CrossRef] [PubMed]
91. Wischik, C.M, Harrington, C.R, Storey, J.M. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem. Pharmacol. 2014, 88, 529-539. [CrossRef] [PubMed]
92. Asuni, A.A, Boutajangout, A, Quartermain, D, Sigurdsson, E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 2007, 27, 9115-9129. [CrossRef] [PubMed]
93. Umeda, T, Eguchi, H, Kunori, Y, Matsumoto, Y, Taniguchi, T, Mori, H, Tomiyama, T. Passive immunotherapy of tauopathy targeting pSer413-tau: A pilot study in mice. Ann. Clin. Transl. Neurol. 2015, 2, 241-255. [CrossRef] [PubMed]
94. Flight, M.H. Neurodegenerative disease: Tau immunotherapy targets transcellular propagation. Nat. Rev. Drug Discov. 2013. [CrossRef] [PubMed]
95. Wischik, C.M, Staff, R.T, Wischik, D.J, Bentham, P, Murray, A.D, Storey, J.M, Kook, K.A, Harrington, C.R. Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer’s disease. J. Alzheimers Dis. 2015, 44, 705-720. [PubMed]